NewLab is using Applied Research to investigate comorbidities associated with psoriasis and possible prognostic factors such as age of onset, severity of disease, and genetic markers among the Newfoundland and Labrador founder population during a 12-year period, 1995/96 to 2006/07.
NewLab is extremely well positioned to capitalize on the pharmaceutical industry’s growing demand for drugs in pre-clinical and early clinical development, and the growing increase in non-chemical drug therapies. NewLab’s ability to identify, develop, and test targets and drugs based on genetic information allows substantial de-risking as well as cost and time savings in drug development. NewLab’s drug development process offers several significant competitive advantages as outlined below.
- NewLab’s access to a founder population for its research and its use of genetic data provides a faster path to identification of disease targets.
- NewLab’s knowledge of biological pathways and gene variants helps to validate targets and eliminate poor target candidates.
- NewLab can execute quicker trials by testing on patients selected for likely high response and safety.
- NewLab can target the optimal population by combining a drug with molecular diagnostic testing.
The overall result is safer, more effective drugs which can command premium prices for more predictable outcomes.
In addition, NewLab’s access to existing drugs for re-purposing has generated a pipeline of products that are already significantly advanced in the drug development process with existing safety and human proof-of-concept data.
|
|
|
|
|